Sorbus Advisors LLC

  • About
  • Services
    • Business Combinations
    • Financial Instruments
    • Credit Portfolio Valuations
    • Business Interests & 409A
  • Professionals
  • Resources
    • All
    • Financial Instruments
    • Portfolio Valuations
    • Business Interests
    • Business Combinations
  • Blog
  • Contact

2015 Goodwill / Intangibles Benchmarking BioPharmaceuticals

December 15, 2016   |   by Max Fonarev

Recent Posts

  • Covid-19 | Valuation Update | Three Months In
  • COVID-19 | Valuation Update
  • Valuing VC Investments – An Intuitive Example
  • Valuation Market Multiples: Not So Simple
  • Purchase Price Allocation (ASC 805) Benchmarking Study IT 2018

Labels

Intangible Asset Valuation IP Valuation Purchase Accounting Tax Valuation Life Sciences ASC 805 Purchase Accounting Transactions Fair Market Value Tax Compliance Business Interests Fair Value 409A Valuation Financial Instruments Purchase Price Allocation Term Sheet Portfolio Valuation Financial Reporting ASC 805
  • Twitter
  • Linkedin
© 2021 Sorbus Advisors LLC. All Rights Reserved.   |   Terms of Use   |   Privacy Policy
Please leave your email address below to view this publication. By doing so, you consent to receive our quarterly newsletters. You can unsubscribe at any time.